I'm LongbridgeAI, I can summarize articles.The Week
Absci (ABSI) gained 11.27% this week to close at $9.18, outperforming the S&P 500 by about 11.74 percentage points as the broader index slipped 0.47%. The stock ran up before giving back part of its gains: it dipped to $8.22 on Tuesday, posted a heavy-volume move to a week high of $10.205 on Wednesday, then eased to $9.18 by Friday. Weekly amplitude was 22.84%, with average daily volume of 3.31m shares, roughly 10.7% above the 60-day median. There was no major company-specific catalyst during the week; the price largely floated higher off the prior close.
Analyst Ratings
As of 22 October, 11 institutions cover Absci: 8 rate it buy, 2 rate it overweight and 1 holds a neutral rating. The consensus rating is strong buy, with a consensus target of $14.9, implying about 62.31% upside from the current price. Targets range from $10.000 to $20.000, pointing to wide disagreement among brokers. Absci ranks 129th within the biotechnology industry in analyst coverage, with coverage breadth above the industry average.
The Week Ahead
The coming week brings a string of US macro releases: Dallas Fed manufacturing activity, durable goods orders, FHFA house prices, Case Shiller home prices, new home sales, Richmond Fed composite index and consumer confidence. The market expects durable goods orders to rebound to 1.5% month-on-month. Absci itself will report fiscal Q3 2026 earnings before the open on 12 November, with estimates at a $0.1926 per-share loss and $613k in revenue, so the next few sessions may start pricing in pre-earnings positioning.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.